Horizon Scanning: Orphan drug status granted for gevokizumab for the treatment of uveitis in the United States

Source: BioSpace Area:News
BioSpace reports that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to gevokizumab, an interleukin-1 beta modulating antibody, for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.
Please see link below for further details.